AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF >40 Percent
Prescription rates increased from 2021 to 2023, but high variance seen between hospitals in the rate of prescriptions
COVID-19, Flu, RSV Vaccine Coverage Low for Nursing Home Residents
As of Nov. 10, 2024, 29.7 percent of nursing home residents had received a 2024 to 2025 COVID-19 vaccine
AHA: Bumetanide Nasal Spray Statistically Bioequivalent to Oral Bumetanide
Nasal spray absorbed more rapidly than oral tablet and has comparable pharmacodynamic effects of diuresis and natriuresis
RSNA: Levothyroxine Tied to Bone Loss Over Time in Older Adults
Authors say findings may be due to relative excess of thyroid hormone even when treatment is targeted to reference range goals
In Utero Exposure to Certain Antiepileptics Tied to Neurodevelopmental Diagnoses
Children exposed to topiramate were 2.5 times more likely to be diagnosed with intellectual disability
COVID-19, Flu, RSV Vaccine Coverage Low for Adults in 2024 to 2025 Season
34.7 percent of adults reported having received influenza vaccine; 17.9 percent received COVID-19 vaccine
Studies Examine Cost-Effectiveness of Maternal RSV Vaccination, Nirsevimab in Infants
Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks
AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With Cardiovascular Risk
Reduction in levels seen using an intact lipoprotein(a) assay and apolipoprotein(a)-based assay
President-Elect Trump Names His Picks to Head the CDC and FDA
In addition, the president-elect has chosen his nominee for surgeon general
FDA Approves Bimzelx for Hidradenitis Suppurativa
Approval based on phase 3 trials showing clinical response at 16 weeks, with sustained benefit at 48 weeks
